"RDIF announces the results of a new study of the Sputnik V coronavirus vaccine in the Republic of Belarus, which has demonstrated a high safety of the drug and an efficacy of 96.3%," the message says.
It is clarified that the analysis was carried out on the basis of a full course of vaccination of 1.2 million people.
The RDIF added that a detailed article on the effectiveness of the vaccine has been published on the medical portal MedRxiv.
Earlier, the head of RDIF, Kirill Dmitriev, said that the fund expects approval of the Sputnik V vaccine by the World Health Organization by the end of 2021.